Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT

Circulation
Erin A BohulaEugene Braunwald

Abstract

Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C and hs-CRP. An analysis of the relationship between achieved LDL-C and hs-CRP targets and outcomes for simvastatin and ezetimibe/simvastatin was prespecified in Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). The IMPROVE-IT trial randomly assigned 18 144 patients stabilized after acute coronary syndrome to simvastatin or ezetimibe/simvastatin. LDL-C and hs-CRP were measured at baseline and 1 month after randomization. Outcomes were assessed in those achieving one or both of the prespecified targets of LDL-C<70 mg/dL and hs-CRP<2 mg/L versus achieving neither target, adjusting for differences in baseline characteristics. An exploratory analysis examined targets of LDL-C<50 mg/dL and hs-CRP<1 mg/L. Patients meeting both targets at baseline, with no 1-month values, or with end points before 1 month were excluded. Of 15 179 patients, 39% achieved the dual LDL-C (<70 mg/dL) and hs-CRP (<2 mg/L) targets at 1 month, 14% met neither target, 14% met only the hs-CRP target, and 33% met only the LDL-C target. Those achieving dual targets had lo...Continue Reading

References

Apr 3, 1997·The New England Journal of Medicine·P M RidkerC H Hennekens
Aug 10, 2000·Journal of the American College of Cardiology·D FerroF Violi
Sep 19, 2002·British Journal of Clinical Pharmacology·Teddy KosoglouMelton B Affrime
Oct 9, 2002·Circulation·Thomas SudhopKlaus von Bergmann
Nov 9, 2002·The American Journal of Cardiology·Claude GagnéUNKNOWN Ezetimibe Study Group
Dec 20, 2002·Nature·Peter Libby
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Jun 15, 2004·The American Journal of Cardiology·Christie M BallantyneJoanne Palmisano
Sep 1, 2004·JAMA : the Journal of the American Medical Association·James A de LemosUNKNOWN Investigators
Jan 7, 2005·The New England Journal of Medicine·Paul M RidkerUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Inv
Oct 31, 2008·The New England Journal of Medicine·Jeppe ZachoBørge G Nordestgaard
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Jul 2, 2009·JAMA : the Journal of the American Medical Association·Paul ElliottJaspal S Kooner
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Jun 20, 2015·Journal of the American College of Cardiology·Robert P Giugliano, Marc S Sabatine

❮ Previous
Next ❯

Citations

Jan 30, 2016·Expert Opinion on Biological Therapy·Marcos G ValerioWilbert S Aronow
Nov 13, 2015·Expert Opinion on Pharmacotherapy·Maria-Corina SerbanDimitri P Mikhailidis
Feb 13, 2016·Journal of the American College of Cardiology·Paul M Ridker
Jan 23, 2016·International Journal of Cardiology·Luca Mascitelli, Mark R Goldstein
Jan 30, 2016·Journal of the American College of Cardiology·R Scott Wright, Joseph Murphy
Mar 10, 2016·Current Opinion in Lipidology·Uwe J F Tietge
Apr 16, 2016·Future Cardiology·Peter P TothAndrew M Tershakovec
May 25, 2016·Current Opinion in Cardiology·Maciej BanachPeter P Toth
Jul 16, 2016·International Journal of Cardiology·Alberto J Lorenzatti, Brenda M Retzlaff
Jul 28, 2016·International Journal of Cardiology·Xue LinUNKNOWN DYSIS-China Study Investigators
Sep 10, 2016·Journal of the American College of Cardiology·Luca Mascitelli, Mark R Goldstein
Dec 16, 2016·Thrombosis and Haemostasis·Donato Santovito, Christian Weber
Dec 9, 2016·Expert Opinion on Emerging Drugs·Marie-Jeanne Bertrand, Jean-Claude Tardif
Feb 16, 2017·European Journal of Preventive Cardiology·John MunkhaugenEinar Husebye
Feb 7, 2017·British Journal of Clinical Pharmacology·Eva DolezelovaAmirhossein Sahebkar
Apr 4, 2017·Expert Opinion on Investigational Drugs·Gerald H Tomkin, Daphne Owens
Jun 18, 2017·European Journal of Preventive Cardiology·David Sinning, Ulf Landmesser
Nov 29, 2016·Nature Communications·Stephen L PinkoskyNarendra D Lalwani
Dec 25, 2016·Expert Review of Cardiovascular Therapy·Fabien HuetFrançois Roubille
May 13, 2017·Vascular Medicine·UNKNOWN Writing Committee MembersDuminda N Wijeysundera
Mar 21, 2018·Current Atherosclerosis Reports·Kevin C Maki, Mary R Dicklin
Apr 11, 2018·European Journal of Preventive Cardiology·John MunkhaugenLars Gullestad
May 4, 2018·European Journal of Preventive Cardiology·Elin Good, Ebo de Muinck
May 16, 2018·European Journal of Preventive Cardiology·Viviane Z Rocha, Raul D Santos
Jun 16, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Annika Lindskog JonssonFredrik Bäckhed
Mar 14, 2018·Circulation·Erin A BohulaMarc S Sabatine
Feb 18, 2017·Circulation Research·Paul M Ridker
Jul 7, 2017·Circulation. Cardiovascular Imaging·Viviany R Taqueti, Paul M Ridker
Oct 16, 2018·Journal of Atherosclerosis and Thrombosis·Kazuo KitagawaUNKNOWN J-STARS collaborators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.